[FIP1L1-PDGFRА-positive myeloproliferative disease with eosinophilia: A rare case with multiple organ dysfunction and a response to tyrosine kinase inhibitor therapy].

Autor: Nemchenko IS; Hematology Research Center, Ministry of Health of Russia, Moscow, Russia., Turkina AG; Hematology Research Center, Ministry of Health of Russia, Moscow, Russia., Chelysheva EY; Hematology Research Center, Ministry of Health of Russia, Moscow, Russia., Galstyan GM; Hematology Research Center, Ministry of Health of Russia, Moscow, Russia., Kovrigina AM; Hematology Research Center, Ministry of Health of Russia, Moscow, Russia., Khuazheva NK; S.P. Botkin City Clinical Hospital, Moscow Healthcare Department, Moscow, Russia., Savchenko VG; Hematology Research Center, Ministry of Health of Russia, Moscow, Russia.
Jazyk: ruština
Zdroj: Terapevticheskii arkhiv [Ter Arkh] 2015; Vol. 87 (12), pp. 89-95.
DOI: 10.17116/terarkh2015871289-95
Abstrakt: The described case of FIP1L1-PDGFRА-positive myeloproliferative disease is characterized by an atypical aggressive course to develop severe specific complications as injuries to the brain, heart, lung, and intestine. Pathogenetic therapy with imatinib could stabilize a patient's state, but failed to produce a complete hematological response. Switching from imatinib to dasatinib could produce sustained clinical, hematological, and molecular remissions.
Databáze: MEDLINE
Externí odkaz: